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Abstract 
With intermittent vitamin D supplementation, serum 25-hydroxyvitamin D (25OHD) levels 
may remain stable only if the dosing interval is shorter than 3 months, the ideal perhaps being 
about 1 month. Recent data support moderate daily vitamin D doses instead of high 
intermittent doses, notably in elderly patients prone to falls. The level of evidence is low, 
however, with no head-to-head comparisons of clinical outcomes such as fractures and falls in 
groups given identical dosages daily versus intermittently. A challenge to daily vitamin D 
supplementation in France is the absence of a suitable pharmaceutical formulation. In 
addition, daily dosing carries a high risk of poor adherence. Until suitable vitamin D3 
formulations such as tablets or soft capsules each containing 1000 or 1500 IU become 
available, we suggest intermittent supplementation according to 2011 GRIO guidelines. 
Among the available dosages, the lowest should be preferred, with the shortest possible 
interval, e.g., 50 000 IU monthly rather than 100 000 every two months.  
  
Keywords: Vitamin D. Osteoporosis. Muscle. Falls. Bone metabolism. Fractures.  
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1. Introduction 
 
In 2011, the French Osteoporosis Research and Information Group (Groupe de 
Recherche et d’Information sur l’Ostéoporose, GRIO) issued recommendations about vitamin 
D supplementation in adults [1]. Since then, new data have emerged, causing changes to 
former concepts. Thus, 24-hydroxylation is now recognized as a major vitamin D-inactivation 
pathway, new clinical definitions of vitamin D deficiency and vitamin D insufficiency have 
been developed, and technical advances have been achieved including the development of a 
reference standard procedure for assaying 25-hydroxy-vitamin D (25OHD). Furthermore, the 
French statutory health insurance system no longer reimburses serum 25OHD assays under all 
circumstances. However, the main reason for this update explaining recent changes in our 
approach is that new evidence challenges current vitamin D supplementation modalities, 
notably the intermittent administration of high dosages.  
Vitamin D contributes to regulate calcium and phosphate metabolism and makes a key 
contribution to musculoskeletal health. Effects of vitamin D include increased intestinal 
absorption of calcium and phosphate; stimulation of fibroblast growth factor 23 (FGF23) 
expression; regulation, in synergy with parathyroid hormone (PTH), of distal renal tubule 
calcium reabsorption and bone turnover; and regulation of PTH release via a feedback loop. 
Profound vitamin D deficiency results in defective bone mineralization, rickets, osteomalacia, 
and diffuse muscle pain. In several randomized placebo-controlled trials, vitamin D 
supplementation, usually given in conjunction with calcium supplementation, decreased the 
risk of nonvertebral fractures in patients older than 65 years [2] and the risk of falls in those 
older than 70 years [3], provided the daily vitamin D intake was at least 20 µg (800 IU) and 
the serum 25OHD level was about 30 ng/mL. Furthermore, osteoporosis medications that act 
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by inhibiting bone resorption, such as bisphosphonates, are fully effective only in patients 
whose serum 25OHD is at least 30 ng/mL [4]. 
In addition to these well-demonstrated effects, vitamin D may have other benefits. Thus, 
numerous observational and experimental studies suggest that vitamin D may prevent a range 
of health conditions including diabetes, cardiovascular disease, certain types of cancer, age-
related cognitive decline, infections, and autoimmune diseases [5]. However, controlled 
interventional studies usually failed to confirm these nonclassical effects of vitamin D, except 
in patients who were vitamin D-deficient at baseline [6] and in those who achieved the target 
serum 25OHD levels defined for the study [7]. Here, we will confine our discussion to the 
musculoskeletal effects of vitamin D in an attempt to define the optimal vitamin D status and 
adequate vitamin D intake.  
 
2. Defining the optimal vitamin D status 
 
The optimal vitamin D status is defined based on the serum 25OHD level. Reference 
ranges for laboratory parameters are usually defined as the range that includes 95% of the 
values found in a healthy population. This method cannot be used for serum 25OHD levels, 
however: as 25OHD levels are significantly lower in winter than in summer, two different 
normal ranges would have to be defined. Consequently, experts agree that a better approach 
consists in determining 25OHD cutoffs below and above which deleterious effects may occur, 
as well as the 25OHD levels associated with beneficial effects, based on the available 
interventional studies. Various cutoffs have been put forward in recommendations about 
managing patients with vitamin D stores. A consensus exists about defining vitamin D 
deficiency as a serum 25OHD level below 10-12 ng/mL, whereas some uncertainty continues 
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to surround the definition of vitamin D insufficiency. It is useful to distinguish two main 
situations depending on the risk of osteoporosis.  
 
2.1. Patients with osteoporosis or at high risk for osteoporosis  
In patients who have osteoporosis or are at high risk for osteoporosis due to treatments 
with potentially deleterious bone effects (e.g., high-dose glucocorticoids, aromatase 
inhibitors, and GnRH analogs) or to health conditions (e.g., primary hyperparathyroidism or 
other endocrinopathies; or malabsorption related to celiac disease, cystic fibrosis, or bypass 
bariatric surgery), patients with chronic kidney disease, and older patients at high risk for 
falls, many experts believe that the serum 25OHD level must be kept at or above 30 ng/mL 
(75 nmol/L) to optimize musculoskeletal strength [1;8-11]. Serum 25OHD assays are 
warranted, before starting the supplementation then during follow-up to adjust the dosage. In 
this patient subset, the GRIO has recommended a loading phase to allow the rapid and 
accurate interpretation of parameters reflecting the calcium and phosphate status, notably the 
serum PTH level. Importantly, a calcium intake of about 1 g/day should be provided in these 
patients. 
 
2.2. The general population of apparently healthy individuals 
For this patient population, the Institute of Medicine in the US recommends supplying 
the vitamin D dose that will allow most individuals to achieve a serum 25OHD level of 20 
ng/mL (50 nmol/L), which is deemed sufficient in this situation [12]. No prior serum 25OHD 
assay is required. 
The upper limit of the desirable serum 25OHD range is currently set at 60 ng/mL, 
which is approximately the highest value found in populations exposed to generous amounts 
of UVB radiation from sunlight year-round [13]. The 60 ng/mL value is also markedly 
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different from the lowest value at which vitamin D poisoning may occur, i.e., 150 ng/mL [14]. 
Another point of interest is that a few observational studies found an upside-down J-shaped 
relationship between the 25OHD level and the relative risk of disease: the risk was higher not 
only in patients with low values, but also, to a lesser extent, in those with values above 60 
ng/mL [15]. Although these observational studies cannot supply information about causality, 
their findings support the choice of 60 ng/mL as the highest desirable serum 25OHD level. 
Studies in the general population in France have found serum 25OHD levels below 
20 ng/mL (50 nmol/L) in about 40%-50% of individuals and below 30 ng/mL (75 nmol/L) in 
80% of individuals [16-18]. 
 
3. Vitamin D supplementation 
 
The goals of vitamin D supplementation are to ensure that serum 25OHD levels are 
between 20 and 60 ng/mL in most individuals in the general population and between 30 and 
60 ng/mL in patients with osteoporosis, chronic kidney disease, or malabsorption. Until very 
recently, standard practice consisted in obtaining a serum 25OHD assay to guide selection of 
the vitamin D dose. Thus, higher doses were given to patients with lower serum 25OHD 
values. This practice made sense but resulted in a large number of 25OHD assays, at 
considerable cost to the healthcare system. The French National Authority for Health (HAS) 
therefore decided to reimburse serum 25OHD assays only for individuals meeting specific 
criteria (http://www.has-sante.fr/portail/jcms/c_1356838/fr/utilite-clinique-du-dosage-de-la-
vitamine-d-rapport-d-evaluation). Many experts feel that these criteria are overly restrictive 
[19].  
Whereas calcium supplements must be taken every day, vitamin D supplements can be 
taken at far wider intervals, due to the long half-life of 25OHD. In France, preparations are 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
8 
 
available for either daily or intermittent administration. Drops for supplying small daily doses 
(300-400 IU of vitamin D per drop) are chiefly used for infants. Tablets and sachets 
combining vitamin D3 and calcium are also available. For intermittent administration, the 
dosages available in France are 50 000, 80 000, 100 000, and 200 000 IU for vitamin D3 and 
600 000 IU for vitamin D2. Patient adherence to daily vitamin D supplementation, notably in 
combination with calcium, is often low [20]. Consequently, intermittent administration is 
currently the preferred method in France. With intermittent administration, two rules must be 
scrupulously followed: only vitamin D3 should be used, as it maintains an optimal vitamin D 
status for far longer than does vitamin D2 [21]; and very high doses at widely spaced intervals 
should not be used, particularly in older women. The second rule is based on several studies. 
In women older than 80 years, a single annual dose of 500 000 IU of vitamin D3 given for 4 
consecutive years increased the risk of both fractures and falls compared to a placebo [22]. 
The excess fractures and falls was significant only during the first 3 months after each annual 
dose. Although surprising, these findings confirm those of a previous study in which men and 
women older than 75 years had a higher hip fracture rate when given annual intramuscular 
injections of 300 000 IU of vitamin D2 instead of a placebo [23].  
In France, when prescribing intermittent vitamin D supplementation in doses of 80 000 
or 100 000 IU, the usual dosing interval is 2 to 3 months, in keeping with earlier 
recommendations [1]. Recent data, however, suggest that a shorter interval may be preferable. 
A randomized controlled trial done in postmenopausal women in Finland compared 25OHD 
levels before and 7 days after treatment with either a placebo or with vitamin D3 in a dosage 
of 100 000 IU or 200 000 IU [24]. Each treatment was given at 3-month intervals. The 
25OHD levels 7 days after dosing were higher in the 200 000 IU group than in the 100 000 IU 
group, as expected, but the 25OHD levels just before the next dose were the same in the two 
vitamin D3 groups. The key messages from this study are that a steeper rise in vitamin D 
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levels induced by supplementation is followed by a steeper decline, and a 3-month interval 
between 100 000 IU or 200 000 IU doses may allow marked fluctuations in 25OHD levels, 
suggesting that a shorter interval may be preferable. This last point is important, as recent 
studies have shown that fluctuations in 25OHD levels are associated with variations in the 
opposite directions in serum levels of PTH and CTX: PTH and CTX levels increase when 
25OHD levels decrease, indicating increased bone resorption that probably adversely affects 
bone health [25]. 
In several studies, 25OHD levels remained similarly stable with daily and monthly 
dosing [26]. A recent randomized trial, however, calls this finding into question. The 
participants were 200 elderly individuals (67% of females) with at least one fall during the 
past year [27]. The treatments were given once a month. One group received 60 000 IU (the 
theoretical equivalent of 2 000 IU/day) of vitamin D3 and another only 24 000 IU of vitamin 
D3. The mean number of falls was significantly higher in the group given the higher dose. 
One possible explanation is that the excess falls were caused by the higher vitamin D3 doses 
and/or higher 25OHD levels. However, a randomized controlled trial done a few years earlier 
by the same group suggests that the intermittent dosing schedule may be the culprit [28]. 
Mean age and proportion of female participants were similar to those in the subsequent study, 
and the inclusion criterion was a recent hip fracture. The fall risk was similar in the groups 
given 800 IU/day and 2000 IU/day. In contrast, readmissions and complications of falls were 
significantly less common in the group given the higher dose. 
Although definitive data are still lacking, the available studies raise many questions 
regarding the best vitamin D supplementation regimen, notably in older individuals. Daily 
dosing instead of the monthly administration of higher doses has been advocated in an 
editorial [29] and a position paper [30]. Several older publications also recommended daily 
dosing [31;32]. Furthermore, metaanalyses assessing the effects of vitamin D supplementation 
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on muscle strength [33] or on the risk of respiratory tract infections [34] found that vitamin D 
supplementation was beneficial when given daily but not when given in high doses at wide 
intervals. 
 
4. Conclusion and perspectives 
 
A few recent studies suggest that moderate daily doses of vitamin D may be preferable 
over larger doses given intermittently in patients who fall. The level of evidence underlying 
this suggestion is low, however. More specifically, no head-to-head comparisons of clinical 
outcomes such as fractures and falls with daily versus intermittent administration of the same 
dosages has been published to date. In addition, daily dosing is challenging given the lack of a 
suitable pharmaceutical formulation and high risk of nonadherence. Similar doses of vitamin 
D given daily or intermittently seem to induce the same decrease in PTH release, an effect 
that is central to the efficacy of vitamin D in improving bone health. A reasonable suggestion 
at present is intermittent supplementation using the lowest available doses and shortest 
possible dosing intervals. For instance, in patients with falls and/or osteoporosis, for whom 
the target is a 25OHD level above 30 ng/mL, the dosage could be determined according to the 
baseline 25OHD level, namely, 50 000 IU/week for 8 weeks if below 20 ng/mL and 50 000 
IU/week for 4 weeks if between 20 and 30 ng/mL (Figure 1). This loading phase can be 
followed by the long-term administration of 50 000 IU/month. A 25OHD assay after 3-6 
months is then necessary to determine whether the dosage needs to be adjusted, given the 
huge interindividual variability in the 25OHD response to vitamin D3, which ranges from 
minimal to very considerable [35]. If the 25OHD level remains below 30 ng/mL, the dosing 
interval can be shortened or the dosage increased to 80 000 or 100 000 IU each month. If the 
25OHD level is above 60 ng/mL, the only available strategy to date, despite being in 
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contradiction to the comments above, consists in lengthening the dosing interval (e.g., 50 000 
IU every 2 months), until lower dosages (e.g., 25 000 IU) become available. 
Should pharmaceutical forms suitable for daily supplementation become available (e.g., 
tablets or soft capsules containing 1000 or 1500 IU of vitamin D3), patients displaying good 
treatment adherence could take a daily dose determined based on the 25OHD level. Thus, for 
patients with 25OHD levels below 20 ng/mL, 3000 to 5000 IU/day for about 3 months could 
be followed by long-term supplementation with 1000 to 3000 IU/day, with adjustments based 
on follow-up 25OHD assays. These suggested treatment regimens are consistent with 
previous recommendations issued by the GRIO [1], which also include intermittent. 
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In patients with or at risk for osteoporosis 
Until daily dosing becomes feasible, intermittent dosing should remain standard practice, 
with the lowest available dosages and shorter dosing intervals. This strategy probably 
improves adherence compared to daily dosing.  
– Start with a loading phase 
 50 000 IU of vitamin D3 per week for 8 weeks in patients whose 25OHD is <20 
ng/mL  
 50 000 IU of vitamin D3 per week for 4 weeks in patients whose 25OHD is between 20 
and 30 ng/mL 
– After this loading phase, prescribe long-term supplementation: 
 50 000 IU of vitamin D3 per month  
– After 3-6 months of this long-term supplementation, repeat the 25OHD 
assay  
 If 25OHD is still <30 ng/mL 
– either shorten the dosing interval (e.g., 50 000 IU every 2 
weeks)  
– or increase the dosage (e.g., to 80 000 or 100 000 IU each 
month)  
 If 25OHD is >60 ng/mL (extremely rare)  
– The only possibility contradicts the recommendations above: 
– increase the dosing interval (e.g., 50 000 UI every 2 months) 
until lower dosages become available 
 
Figure 1: Modalities of vitamin D supplementation for patients with vitamin D deficiency or 
insufficiency 
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